---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Economic impact of diagnostic testing"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Economic impact of diagnostic testing. Topics: Inpatient 72-hour fast for insulinoma: duration and cost (quality improvement report), Prolonged fasting test when hypoglycemia does not occur spontaneously (insulinoma), and Availability of big IGF-II measurement for NICTH diagnosis. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Inpatient 72-hour fast for insulinoma: duration and cost (quality improvement report)

> “test for detecting insulinoma but imposes significant burdens on patients and expends hospital resources.”
> “The original protocol had an average fast duration of 57.6 hours (median 72 hours, IQR [49,72]).”
> “This reduced cumulative inpatient fasting by 376.5 hours and reduced medical costs.”
> “Adding a BHB >2.7 mmol/L stopping criterion reduced inpatient hospitalization time, medical costs, and patient burden without compromising insulinoma detection.”

Source: [Lundholm et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40288609/)

<a id="topic-2.2.1.8.4-2"></a>

### Prolonged fasting test when hypoglycemia does not occur spontaneously (insulinoma)

> “If hypoglycemia does not occur spontaneously, a 72-hour prolonged fasting test should be performed and blood should be drawn for measurements of insulin, and pro-insulin, or C-peptide measurements if hypoglycemia occurs.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.8.4-3"></a>

### Availability of big IGF-II measurement for NICTH diagnosis

> “To our knowledge, there is no commercially available assay for big IGF-II, and measurement of high molecular weight precursor forms of IGF-II must be done in a research laboratory setting at this time.”
> “Nevertheless, a widely available assay would assist all practitioners, especially those without access to a research laboratory.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.1.8.4-4"></a>

### Cost of diagnostic testing for tumor hyperinsulinism

No evidence found.

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
